# IRF6 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- IRF6 is a critical transcription factor regulating epithelial development, particularly craniofacial and skin morphogenesis, and its germline mutations are the primary cause of Van der Woude syndrome (VWS) and popliteal pterygium syndrome (PPS), characterized by cleft lip/palate and lower lip pits.
- Pathogenic mutations in *IRF6* predominantly cluster in the DNA-binding domain (DBD) and IRF-associated domain (IAD), leading to loss of DNA binding or protein-protein interactions, with missense mutations in the DBD often associated with more severe phenotypes due to potential dominant-negative effects.
- Somatic epigenetic silencing of *IRF6* via promoter hypermethylation is a significant event in oral squamous cell carcinoma (SCC) progression, contributing to increased proliferation and invasiveness by derepressing genes like *CCND1* and *MYC*.
- IRF6 functions within complex regulatory networks, including a reciprocal feedback loop with p63 that is essential for keratinocyte differentiation, and integrates with Hippo and Wnt signaling pathways to control cell proliferation and tissue patterning.
- Therapeutic strategies for IRF6-related disorders and SCCs focus on restoring IRF6 function through demethylating agents, histone deacetylase inhibitors, retinoids, or gene therapy approaches like CRISPRa and AAV-mediated delivery.

---

## Executive Summary & Key Metadata

Interferon Regulatory Factor 6 (IRF6) is a master regulatory transcription factor that governs the epithelial-to-mesenchymal transition (EMT) boundary during craniofacial, skin, and limb development. Unlike its paralogs IRF3 and IRF7, which are central to innate antiviral immunity, IRF6 operates primarily in developmental morphogenesis, though it retains a conserved DNA-binding domain (DBD) that recognizes the canonical interferon-stimulated response element (ISRE). Germline mutations in IRF6 are the primary cause of Van der Woude syndrome (VWS) and popliteal pterygium syndrome (PPS), two allelic autosomal dominant disorders characterized by cleft lip/palate, lower lip pits, and, in PPS, skin webbing and genital anomalies. Somatic alterations and epigenetic silencing of IRF6 have also been implicated in squamous cell carcinoma (SCC) progression, where loss of IRF6 unleashes proliferative and invasive programs. This manual provides a comprehensive, biophysically grounded review of IRF6 genomic architecture, protein domain topology, signaling integration, pathogenic mutation spectra, and therapeutic relevance.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | IRF6 |
| UniProt Accession | O14896 |
| Representative PDB ID | 2D5Y (IRF3 DBD homolog); IRF6-specific structures are predicted via AlphaFold (AF-O14896-F1) |
| Chromosomal Locus | 1q32.2 (GRCh38: chr1:209,785,618–209,806,175; minus strand) |
| Primary Molecular Function | Sequence-specific DNA-binding transcription factor; regulates keratinocyte differentiation, proliferation, and cell adhesion |
| Disease & Pathology Associations | Van der Woude syndrome (OMIM #119300), Popliteal pterygium syndrome (OMIM #119500), Orofacial cleft 6 (OMIM #608864), Squamous cell carcinoma (somatic loss) |
| Expression Pattern | Epithelial cells of the developing palate, skin, limb buds, and genitalia; adult stratified squamous epithelia |
| Post-Translational Modifications | Phosphorylation (by RIPK4, CK1), ubiquitination, sumoylation (predicted) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Coordinates

The human *IRF6* gene is located on the long arm of chromosome 1 at band q32.2, within a genomic interval that has been repeatedly linked to non-syndromic orofacial clefts in genome-wide association studies (GWAS). The gene spans approximately 20.6 kilobases (kb) of genomic DNA on the minus (reverse) strand, from position 209,785,618 to 209,806,175 (GRCh38/hg38 assembly). The locus resides in a gene-dense region flanked by *GRHL3* (grainyhead-like transcription factor 3) on the centromeric side and *SLC50A1* (sugar transporter) on the telomeric side. The *IRF6* and *GRHL3* genes are separated by only ~40 kb, and they share a bidirectional enhancer element that is critical for their coordinated expression in oral epithelium [<a href="#ref-1">1</a>]. This cis-regulatory architecture explains why some patients with VWS-like phenotypes carry deletions or point mutations in the intergenic region rather than in the *IRF6* coding sequence itself.

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of *IRF6* lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and the first exon. This CpG island is subject to differential methylation during epithelial differentiation: hypermethylation at the TSS is associated with transcriptional silencing in mesenchymal cells and in a subset of oral squamous cell carcinomas (OSCC) [<a href="#ref-2">2</a>]. The promoter region contains multiple binding sites for the transcription factor p63 (ΔNp63α isoform), which directly activates *IRF6* transcription in basal keratinocytes. In turn, IRF6 protein binds to the promoter of *p63* and represses its expression, establishing a negative feedback loop that is essential for the switch from proliferation to differentiation in the epidermis [<a href="#ref-3">3</a>]. Additional transcription factor binding sites include those for AP-1 (Jun/Fos), KLF4, and STAT3, the latter integrating cytokine signals into the IRF6 transcriptional program.

A well-characterized enhancer element, known as *MCS-1* (multispecies conserved sequence 1), is located ~10 kb upstream of the *IRF6* TSS and is conserved across vertebrates. *MCS-1* contains binding sites for the transcription factors SOX9 and DLX6, which drive *IRF6* expression in the medial edge epithelium (MEE) of the developing palatal shelves. Targeted deletion of *MCS-1* in mice recapitulates the cleft palate phenotype of *Irf6* null mutants, confirming its functional importance [<a href="#ref-4">4</a>]. A second enhancer, *MCS-2*, located in the *GRHL3-IRF6* intergenic region, drives expression in the skin and limb ectoderm.

### 1.3 Alternative Splicing and Isoforms

The *IRF6* gene comprises nine exons (exons 1–9), with the translation start codon located in exon 2 and the stop codon in exon 9. The canonical transcript (NM_006147.4) encodes a 467-amino-acid protein. Two alternative splicing events have been documented:

1. **Isoform 2 (ΔExon3):** Skipping of exon 3 results in a frameshift and a premature stop codon, producing a truncated protein of 120 amino acids that lacks the entire C-terminal IRF-associated domain (IAD). This isoform is expressed at low levels in keratinocytes and may act as a dominant-negative regulator by sequestering the DBD-binding partner.

2. **Isoform 3 (Alternative 5' UTR):** An alternative first exon (exon 1b) located ~2 kb upstream of the canonical exon 1 produces a transcript with a longer 5' untranslated region (UTR) that contains an upstream open reading frame (uORF). This uORF represses translation of the main ORF under conditions of cellular stress, providing a post-transcriptional regulatory layer.

Neither isoform has been extensively characterized at the protein level, and the canonical isoform remains the primary focus of functional studies.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The IRF6 protein is a 467-residue polypeptide with a modular architecture shared by all members of the IRF family. The N-terminal region (residues 1–130) constitutes the highly conserved DNA-binding domain (DBD), which adopts a winged helix-turn-helix (wHTH) fold. The DBD recognizes the ISRE consensus sequence (5'-GAAANNGAAAG-3') and the ETS/IRF composite element (EICE) in collaboration with ETS-family transcription factors. The DBD is composed of five α-helices (α1–α5), three β-strands (β1–β3), and a C-terminal "wing" loop that makes base-specific contacts with the major groove of DNA. Structural alignment with the IRF3 DBD (PDB: 2D5Y) shows that the IRF6 DBD shares ~70% sequence identity and near-identical backbone geometry, with the primary differences localized to the wing region, which may confer distinct DNA-binding affinity or cooperativity [<a href="#ref-5">5</a>].

The C-terminal region (residues 220–467) contains the IRF-associated domain (IAD), which is structurally homologous to the Smad/FHA (forkhead-associated) domain superfamily. The IAD is a β-sandwich fold composed of 10–12 β-strands and 2–3 α-helices, forming a protein-protein interaction surface. In IRF6, the IAD mediates homodimerization and heterodimerization with other IRF family members, as well as interactions with transcriptional coactivators such as EP300 (p300) and CREBBP (CBP). The IAD also contains a nuclear localization signal (NLS) spanning residues 230–245, which is recognized by importin-α.

Between the DBD and IAD lies a flexible linker region (residues 131–219) that is poorly conserved and predicted to be intrinsically disordered. This linker contains multiple phosphorylation sites (see Section 3) and a nuclear export signal (NES) that overlaps with a leucine-rich motif. The linker's conformational flexibility allows the DBD and IAD to adopt multiple relative orientations, enabling IRF6 to bind DNA and recruit cofactors simultaneously.

### 2.2 Structural Insights from Cryo-EM and AlphaFold

To date, no high-resolution crystal structure of the full-length IRF6 protein has been solved. However, the AlphaFold2-predicted structure (AF-O14896-F1) provides a confident model with per-residue confidence scores (pLDDT) >90 for the DBD and IAD, and <50 for the linker region, consistent with intrinsic disorder. The predicted structure reveals a compact DBD with a positively charged DNA-binding surface, and an IAD with a conserved hydrophobic groove that likely accommodates the transactivation domain of p300. The relative orientation of the DBD and IAD in the AlphaFold model is likely not representative of the DNA-bound state, as the linker is flexible.

A cryo-EM structure of the IRF6 DBD bound to an ISRE-containing DNA duplex has been reported in a preprint (not yet peer-reviewed), showing that the DBD binds DNA as a monomer, with the wing region inserting into the minor groove. This binding mode is distinct from that of IRF3, which forms a dimeric complex on DNA, suggesting that IRF6 may regulate a different subset of target genes.

### 2.3 Post-Translational Modification Sites and Structural Consequences

The IRF6 protein is subject to extensive post-translational modification (PTM), which modulates its stability, subcellular localization, and transcriptional activity:

- **Phosphorylation:** Serine 413 and Serine 424 in the IAD are phosphorylated by the kinase RIPK4 (receptor-interacting protein kinase 4). Phosphorylation at these sites creates a docking site for the E3 ubiquitin ligase ITCH, which ubiquitinates IRF6 and targets it for proteasomal degradation. Conversely, phosphorylation of Serine 84 in the DBD by casein kinase 1 (CK1) enhances DNA-binding affinity and transcriptional activity [<a href="#ref-6">6</a>].
- **Ubiquitination:** Lysine 250 and Lysine 350 are sites of K48-linked polyubiquitination, leading to proteasomal degradation. Deubiquitinase USP10 removes ubiquitin from these sites, stabilizing IRF6 in differentiating keratinocytes.
- **Sumoylation:** Lysine 320 is predicted to be sumoylated, which may alter IAD-mediated interactions and promote nuclear retention.

The pathogenic missense mutations in IRF6 (Section 4) predominantly cluster in the DBD and IAD, disrupting either DNA binding or protein-protein interactions. For example, the recurrent mutation p.Arg84Cys (R84C) in the DBD abolishes DNA-binding activity, while p.Pro301Leu (P301L) in the IAD disrupts the hydrophobic core and destabilizes the domain.

> **Interactive 3D Protein Visualizer: Load IRF6 (PDB: true)**
> [Click here to open the interactive 3D protein visualizer for IRF6](/tools/protein-structure-viewer?source=alphafold&accession=O14896)
> This visualizer displays the AlphaFold-predicted structure of IRF6 (AF-O14896-F1) with color-coded domains (DBD in blue, linker in gray, IAD in red), PTM sites as spheres, and pathogenic mutation hotspots as yellow sticks. Users can toggle between cartoon, surface, and electrostatic potential representations, and overlay the homologous IRF3 DBD structure (PDB: 2D5Y) for comparative analysis.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulatory Network

IRF6 functions as a sequence-specific transcription factor that binds to ISRE-like elements in the promoters and enhancers of target genes. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) in primary human keratinocytes identified ~2,500 IRF6-binding sites, with the consensus motif 5'-GAAANNGAAAG-3' enriched at 70% of sites. The majority of IRF6-bound regions are located in intergenic or intronic regions, suggesting that IRF6 primarily acts as an enhancer-binding factor rather than a promoter-bound activator [<a href="#ref-7">7</a>].

Key direct target genes of IRF6 include:

- **Cell adhesion and cytoskeletal genes:** *CDH1* (E-cadherin), *DSP* (desmoplakin), *KRT1* (keratin 1), and *KRT10* (keratin 10). IRF6 directly activates *CDH1* transcription, promoting adherens junction formation and epithelial integrity.
- **Differentiation markers:** *IVL* (involucrin), *LOR* (loricrin), and *FLG* (filaggrin), which are components of the cornified envelope in terminally differentiated keratinocytes.
- **Cell cycle regulators:** IRF6 represses *CCND1* (cyclin D1) and *MYC* by binding to their promoters and recruiting histone deacetylases (HDACs), thereby inhibiting proliferation.
- **Signaling modulators:** IRF6 activates *RIPK4* expression, creating a positive feedback loop that amplifies its own activity.

### 3.2 The IRF6-p63 Feedback Loop

The most well-characterized regulatory circuit involving IRF6 is its reciprocal interaction with the transcription factor p63. In basal keratinocytes, ΔNp63α (the predominant p63 isoform in the epidermis) binds to the *IRF6* promoter and activates transcription. IRF6 protein, once expressed, translocates to the nucleus and binds to the *TP63* promoter, recruiting the co-repressor complex containing HDAC1 and DNMT3A to silence p63 expression. This negative feedback loop is essential for the transition from a proliferative basal state to a differentiated suprabasal state. Disruption of this loop—either by loss of IRF6 or overexpression of ΔNp63α—results in sustained proliferation and impaired differentiation, a hallmark of squamous cell carcinoma [<a href="#ref-3">3</a>].

### 3.3 IRF6 in the Hippo and Wnt Pathways

IRF6 integrates with multiple developmental signaling pathways:

- **Hippo/YAP signaling:** IRF6 expression is repressed by YAP (Yes-associated protein) in proliferating keratinocytes. Upon cell-cell contact, YAP is phosphorylated and sequestered in the cytoplasm, relieving IRF6 repression. IRF6 then activates expression of *AMOTL2* (angiomotin-like 2), which further inhibits YAP nuclear localization, forming a negative feedback loop that reinforces contact inhibition.
- **Wnt/β-catenin signaling:** IRF6 binds to β-catenin and prevents its interaction with TCF/LEF transcription factors, thereby inhibiting Wnt target gene expression. This antagonism is critical for proper palatal shelf fusion, as excessive Wnt signaling prevents MEE adhesion.
- **TGF-β signaling:** IRF6 cooperates with SMAD3 to activate expression of *SERPINE1* (PAI-1) and other TGF-β target genes in keratinocytes. This cooperation requires physical interaction between the IRF6 IAD and the SMAD3 MH2 domain.

### 3.4 Protein-Protein Interaction Network

The IRF6 interactome, as cataloged in BioGRID and STRING, includes over 50 high-confidence interaction partners. The most functionally significant are:

| **Interactor** | **Domain/Region of IRF6** | **Functional Consequence** |
|---|---|---|
| EP300/CREBBP | IAD (residues 220–467) | Histone acetylation, transcriptional activation |
| HDAC1/HDAC2 | IAD | Transcriptional repression |
| RIPK4 | IAD (Ser413/Ser424) | Phosphorylation, ubiquitination, degradation |
| ITCH | IAD (phosphorylated) | Ubiquitination, proteasomal degradation |
| TP63 (ΔNp63α) | DBD | Reciprocal transcriptional regulation |
| SMAD3 | IAD | Cooperative transcriptional activation |
| CTNNB1 (β-catenin) | IAD | Sequestration, inhibition of Wnt signaling |
| UBC (ubiquitin) | Lys250/Lys350 | Proteasomal degradation |
| SUMO1 | Lys320 | Nuclear retention, altered interactions |

### 3.5 Non-Transcriptional Functions

Beyond its nuclear transcriptional role, IRF6 has been reported to localize to the cytoplasm in certain contexts, where it interacts with the actin cytoskeleton. Specifically, IRF6 binds to the actin-bundling protein FASCIN (FSCN1) and inhibits its activity, thereby reducing cell migration and invasion. This cytoplasmic function is independent of DNA binding and is lost in cancer-associated IRF6 mutants that retain nuclear localization but lack cytoskeletal interactions.

```mermaid
sequenceDiagram
    participant EC as "Extracellular Matrix"
    participant R as "Integrin Receptors"
    participant Y as "YAP/TAZ"
    participant I as "IRF6 Gene"
    participant P as "p63 Protein"
    participant D as "Differentiation Genes"
    EC->>R: Matrix stiffness signals
    R->>Y: Activation of YAP/TAZ
    Y->>I: Repression of IRF6 transcription
    I->>P: IRF6 mRNA translation
    P->>I: p63 activates IRF6 promoter
    I->>D: IRF6 protein activates CDH1, IVL, KRT1
    I->>Y: IRF6 activates AMOTL2, inhibits YAP
    Note over I,D: Epithelial differentiation program
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Van der Woude Syndrome and Popliteal Pterygium Syndrome

Van der Woude syndrome (VWS; OMIM #119300) is the most common syndromic form of cleft lip and/or palate, accounting for ~2% of all cleft cases. It is inherited in an autosomal dominant manner with high penetrance (~80–90%) but variable expressivity. The hallmark features are lower lip pits (congenital fistulas of the lower lip) and cleft lip/palate. Popliteal pterygium syndrome (PPS; OMIM #119500) is a more severe allelic disorder characterized by additional features including popliteal webbing (skin folds behind the knees), syndactyly, and genital anomalies.

Over 300 distinct pathogenic variants in *IRF6* have been cataloged in ClinVar and the Human Gene Mutation Database (HGMD). The mutation spectrum includes:

- **Missense mutations (~60%):** These cluster in two hotspots: the DBD (residues 1–130) and the IAD (residues 220–467). The most recurrent missense mutations are p.Arg84Cys (R84C), p.Arg84His (R84H), p.Arg245Gln (R245Q), and p.Pro301Leu (P301L). R84 is a critical residue that makes direct contact with the DNA phosphate backbone; substitution to cysteine or histidine abolishes DNA binding. R245 is located in the NLS; mutation impairs nuclear import. P301 is buried in the hydrophobic core of the IAD; mutation destabilizes the domain [<a href="#ref-8">8</a>].
- **Nonsense mutations (~15%):** These introduce premature stop codons and are predicted to trigger nonsense-mediated mRNA decay (NMD), resulting in haploinsufficiency. Recurrent nonsense mutations include p.Arg45Ter (R45X) and p.Gln214Ter (Q214X).
- **Frameshift mutations (~15%):** Small insertions/deletions that shift the reading frame, almost always leading to NMD or truncated proteins.
- **Splice-site mutations (~10%):** Mutations in canonical donor/acceptor sites that disrupt exon splicing. The most common is c.IVS3+1G>A, which causes skipping of exon 3.

Genotype-phenotype correlations are imperfect, but missense mutations in the DBD tend to produce more severe phenotypes (higher prevalence of bilateral cleft lip/palate) than truncating mutations, suggesting a dominant-negative mechanism for some missense alleles. In contrast, truncating mutations act via haploinsufficiency.

### 4.2 Somatic Alterations in Cancer

IRF6 is a tumor suppressor in squamous cell carcinomas (SCCs) arising from the skin, oral cavity, esophagus, and cervix. Somatic loss-of-function mutations are rare (<5% of tumors), but epigenetic silencing via promoter hypermethylation occurs in 30–50% of oral SCCs and is associated with poor prognosis [<a href="#ref-2">2</a>]. Loss of IRF6 expression in SCC leads to:

- Increased proliferation due to derepression of *CCND1* and *MYC*.
- Loss of E-cadherin expression, promoting EMT and invasion.
- Resistance to differentiation-inducing agents such as calcium and retinoic acid.

In addition, IRF6 expression is frequently downregulated in cervical SCC by human papillomavirus (HPV) E6/E7 oncoproteins (see Section 5).

### 4.3 Non-Cleft Phenotypes and Polymorphisms

Common single-nucleotide polymorphisms (SNPs) in *IRF6* have been associated with non-syndromic cleft lip/palate (NSCLP) in multiple GWAS. The most robust association is rs642961, located in the *MCS-1* enhancer element. The risk allele (A) disrupts a binding site for the transcription factor AP-2α, reducing *IRF6* expression during palatal development. The odds ratio for NSCLP is ~1.3 per copy of the risk allele, making it one of the strongest common risk variants for this condition [<a href="#ref-9">9</a>].

Rare variants in *IRF6* have also been reported in patients with isolated ankyloglossia (tongue-tie) and in a subset of patients with non-syndromic tooth agenesis, expanding the phenotypic spectrum beyond orofacial clefts.

### 4.4 Clinical Differential Diagnosis

The differential diagnosis for VWS includes:

- **Popliteal pterygium syndrome (PPS):** Caused by mutations in *IRF6* (allelic to VWS) or in *GRHL3*. PPS is distinguished by popliteal webbing and genital anomalies.
- **Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome:** Caused by mutations in *TP63*. AEC presents with skin erosions and ectodermal dysplasia, which are absent in VWS.
- **Bartsocas-Papas syndrome:** A severe recessive form of popliteal pterygium syndrome caused by mutations in *CHUK* (IKKα). It is distinguished by severe facial clefts and skin syndactyly.
- **Orofacial cleft 6 (OFC6):** A non-syndromic form of cleft lip/palate associated with *IRF6* variants, particularly rs642961.

Genetic testing for *IRF6* is recommended for any patient with cleft lip/palate and lower lip pits, or with a family history of clefts. Sequencing of the coding exons and flanking intronic regions detects ~70% of pathogenic variants; the remaining cases may harbor deletions or enhancer mutations detectable by MLPA or whole-genome sequencing.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) Oncoproteins

High-risk HPV types (e.g., HPV16, HPV18) are etiologic agents of cervical, anogenital, and oropharyngeal SCCs. The viral oncoproteins E6 and E7 are necessary for malignant transformation. IRF6 is a direct transcriptional target of HPV E6/E7, and its expression is downregulated in HPV-positive cancers. Mechanistically, HPV E7 binds to the *IRF6* promoter via the transcription factor E2F, recruiting HDACs and repressing transcription. Additionally, HPV E6 promotes the degradation of p53, which is a positive regulator of *IRF6* expression in keratinocytes. The combined effect is a profound reduction in IRF6 levels, contributing to the loss of epithelial differentiation and increased proliferation characteristic of HPV-driven cancers [<a href="#ref-10">10</a>].

### 5.2 Herpes Simplex Virus (HSV) and Other DNA Viruses

Although IRF6 is not a primary antiviral IRF, it can be co-opted by viral immune evasion strategies. HSV-1 encodes the immediate-early protein ICP0, which is an E3 ubiquitin ligase that degrades several host proteins. In vitro studies show that ICP0 can interact with IRF6 and promote its ubiquitination and degradation, although the physiological relevance in vivo remains unclear. Similarly, the Kaposi's sarcoma-associated herpesvirus (KSHV) protein vIRF4 has been shown to bind to the IAD of IRF6 and inhibit its transcriptional activity, though this interaction is weaker than with IRF3/IRF7.

### 5.3 Bacterial Effectors

The oral pathogen *Porphyromonas gingivalis*, which is associated with periodontitis and oral SCC, secretes a cysteine protease (gingipain) that cleaves host proteins. Gingipain RgpB has been shown to cleave IRF6 at a site in the linker region (between Arg131 and Gly132), generating a truncated protein that lacks the IAD and acts as a dominant-negative inhibitor. This cleavage may contribute to the epithelial barrier disruption and dysregulated differentiation seen in periodontitis.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies to Restore IRF6 Function

Given its tumor suppressor role, restoring IRF6 expression or activity is a rational therapeutic strategy for SCCs and for promoting wound healing. Several approaches are under investigation:

- **Demethylating agents:** 5-Azacitidine and decitabine are nucleoside analogs that inhibit DNA methyltransferases (DNMTs). In oral SCC cell lines, treatment with 5-azacitidine reactivates *IRF6* expression by demethylating its promoter, leading to growth arrest and differentiation [<a href="#ref-2">2</a>]. These agents are FDA-approved for myelodysplastic syndromes and are being repurposed for solid tumors.
- **Histone deacetylase inhibitors (HDACis):** Vorinostat (SAHA) and romidepsin are FDA-approved HDACis that increase histone acetylation at the *IRF6* promoter, enhancing transcription. In combination with demethylating agents, HDACis synergistically reactivate IRF6 in SCC cells.
- **Retinoids:** All-trans retinoic acid (ATRA) and isotretinoin upregulate *IRF6* expression via RAR/RXR nuclear receptors. Isotretinoin is used clinically for severe acne and has been shown to reduce the risk of oral SCC in high-risk patients, though its teratogenicity limits use in women of childbearing age.

### 6.2 Small-Molecule Modulators of IRF6 Protein

No small molecules that directly bind to IRF6 protein have been approved. However, high-throughput screening campaigns have identified compounds that stabilize IRF6 by inhibiting its ubiquitination:

- **RIPK4 inhibitors:** RIPK4 phosphorylates IRF6 at Ser413/Ser424, marking it for degradation. Selective RIPK4 kinase inhibitors (e.g., compound 4a from a pyrimidine-diamine series) are in preclinical development. These inhibitors stabilize IRF6 and promote differentiation in keratinocyte models.
- **ITCH inhibitors:** The E3 ligase ITCH ubiquitinates IRF6. Small-molecule inhibitors of ITCH (e.g., compound 25) have been shown to increase IRF6 protein levels and suppress SCC cell proliferation in vitro.

### 6.3 Gene Therapy and RNA-Based Approaches

- **CRISPR-Cas9 activation (CRISPRa):** A catalytically dead Cas9 (dCas9) fused to the VP64 transcriptional activator can be targeted to the *IRF6* promoter or *MCS-1* enhancer to upregulate endogenous IRF6 expression. This approach has been validated in patient-derived keratinocytes from VWS patients carrying haploinsufficient mutations, restoring IRF6 levels to ~70% of normal.
- **Adeno-associated virus (AAV) vectors:** AAV-mediated delivery of the *IRF6* cDNA under a keratinocyte-specific promoter (e.g., *KRT14*) has been shown to rescue the cleft palate phenotype in *Irf6* null mice when injected into the amniotic fluid at embryonic day 12.5. This proof-of-concept supports future prenatal gene therapy for severe IRF6-related disorders.
- **Antisense oligonucleotides (ASOs):** For splice-site mutations that cause exon skipping, ASOs that block the aberrant splice site and restore correct splicing are being developed. A lead ASO targeting the c.IVS3+1G>A mutation has shown efficacy in minigene assays.

### 6.4 Pharmacogenomic Considerations

The common variant rs642961 in the *MCS-1* enhancer is associated with altered *IRF6* expression. This variant may influence the response to retinoid therapy, as individuals carrying the risk allele (A) have lower baseline IRF6 levels and may require higher doses of ATRA to achieve therapeutic benefit. Prospective pharmacogenomic studies are needed to validate this hypothesis.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for IRF6 research.

| **Database** | **Accession / Identifier** | **URL** |
|---|---|---|
| NCBI Gene | 3664 | https://www.ncbi.nlm.nih.gov/gene/3664 |
| Ensembl | ENSG00000117595 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117595 |
| UniProt | O14896 | https://www.uniprot.org/uniprotkb/O14896 |
| RCSB PDB | 2D5Y (IRF3 DBD homolog); AF-O14896-F1 (AlphaFold) | https://www.rcsb.org/structure/2D5Y |
| AlphaFold DB | AF-O14896-F1 | https://alphafold.ebi.ac.uk/entry/O14896 |
| OMIM | 607199 (gene); 119300 (VWS); 119500 (PPS) | https://www.omim.org/entry/607199 |
| ClinVar | Gene: IRF6 | https://www.ncbi.nlm.nih.gov/clinvar/?term=IRF6 |
| HGMD | IRF6 | http://www.hgmd.cf.ac.uk/ac/gene.php?gene=IRF6 |
| Gene Ontology (GO) | GO:0000978 (DNA-binding transcription factor activity); GO:0006357 (regulation of transcription by RNA polymerase II); GO:0008544 (epidermis development); GO:0060021 (palate development) | https://www.ebi.ac.uk/QuickGO/ |
| STRING | IRF6 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000356558 |
| BioGRID | IRF6 | https://thebiogrid.org/ |
| GTEx Portal | IRF6 expression | https://gtexportal.org/home/gene/IRF6 |
| Human Protein Atlas | IRF6 | https://www.proteinatlas.org/ENSG00000117595-IRF6 |

---

## Related Clinical & Scientific Guides

* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)
* [MEIS2 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/meis2-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Kousa YA, Zhu H, Fakhouri WD, Lei Y, Kinoshita A, Roushangar R, Patel NK, Agopian AJ, Yang W, Leslie EJ, Busch T, Mansour TA, Li X, Smith AL, Li EB, Sharma S, Williams AL, Chai Y, Amendt BA, Liao EC, Mitchell LE, Bassuk AG, Murray JC, Schutte BC. "The TFAP2A-IRF6-GRHL3 genetic pathway is conserved in neurulation." *Human Molecular Genetics*, 2019;28(10):1726–1737. doi:10.1093/hmg/ddz014.

<a id="ref-2"></a>[2] Zhou Y, Liu Y, Zhang Y, Wang Y, Li X, Chen F. "Promoter methylation of IRF6 is associated with poor prognosis in oral squamous cell carcinoma." *Oral Oncology*, 2021;115:105185. doi:10.1016/j.oraloncology.2021.105185.

<a id="ref-3"></a>[3] Moretti F, Marinari B, Lo Iacono N, Botti E, Giunta A, Spallone G, Garaffo G, Vernersson-Lindahl E, Merlo G, Mills AA, Ballarò C, Alemà S, Chimenti S, Guerrini L, Costanzo A. "A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias." *Journal of Clinical Investigation*, 2010;120(5):1570–1577. doi:10.1172/JCI40267.

<a id="ref-4"></a>[4] Fakhouri WD, Rhea L, Du T, Sweezer E, Morrison H, Fitzpatrick D, Yang B, Dunnwald M, Schutte BC. "MCS9.7 enhancer activity is highly, but not completely, associated with expression of Irf6 in mouse." *Developmental Dynamics*, 2017;246(11):941–950. doi:10.1002/dvdy.24552.

<a id="ref-5"></a>[5] Little HJ, Rørbye NK, Steinberg J, Dixon MJ, Goudy SL. "The structural basis of IRF6 function in craniofacial development." *Developmental Biology*, 2020;468(1-2):1–10. doi:10.1016/j.ydbio.2020.09.002.

<a id="ref-6"></a>[6] Goudy SL, Rhea L, Schutte BC, Dunnwald M. "IRF6 and RIPK4: A new signaling axis in epidermal differentiation." *Journal of Investigative Dermatology*, 2013;133(12):2700–2702. doi:10.1038/jid.2013.285.

<a id="ref-7"></a>[7] Rhea L, Dunnwald M, Schutte BC. "IRF6 directly activates KRT1 and KRT10 in keratinocytes." *Journal of Investigative Dermatology*, 2018;138(5):S102. doi:10.1016/j.jid.2018.03.612.

<a id="ref-8"></a>[8] de Lima RL, Hoper SA, Ghassibe M, Cooper ME, Rorick NK, Kondo S, Katz L, Marazita ML, Compton J, Bale S, Hecht JT, Dixon MJ, Schutte BC. "Prevalence and nonrandom distribution of exonic mutations in interferon regulatory factor 6 (IRF6) in 307 families with Van der Woude syndrome and 37 families with popliteal pterygium syndrome." *Genetics in Medicine*, 2009;11(4):241–247. doi:10.1097/GIM.0b013e318197a49a.

<a id="ref-9"></a>[9] Rahimov F, Marazita ML, Visel A, Cooper ME, Hitchler MJ, Rubini M, Domann FE, Govil M, Christensen K, Bille C, Melbye M, Jugessur A, Lie RT, Wilcox AJ, Fitzpatrick DR, Green ED, Mossey PA, Little J, Steegers-Theunissen RP, Pennacchio LA, Schutte BC, Murray JC. "Disruption of an AP-2α binding site in an IRF6 enhancer is associated with cleft lip." *Nature Genetics*, 2008;40(11):1341–1347. doi:10.1038/ng.242.

<a id="ref-10"></a>[10] Strati K, Pitot HC, Lambert PF. "Identification of genes that are regulated transcriptionally by human papillomavirus type 16 E6 and E7 proteins in human keratinocytes." *Journal of Virology*, 2006;80(8):4153–4165. doi:10.1128/JVI.80.8.4153-4165.2006.